Case Report

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma

Thaninee Prasoppokakorn, Kessarin Thanapirom, and Sombat Treeprasertsuk

1Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
3Liver Fibrosis and Cirrhosis Research Unit, Chulalongkorn University, Bangkok, Thailand

Correspondence should be addressed to Sombat Treeprasertsuk; battan5410@gmail.com

Received 14 February 2022; Accepted 3 August 2022; Published 5 September 2022

Copyright © 2022 Thaninee Prasoppokakorn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lenvatinib, an oral small-molecule multiple tyrosine kinase inhibitor (TKI), has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC). Proteinuria is one of the most common adverse events associated with lenvatinib treatment. We reported a 67-year-old Thai female was diagnosed with NASH cirrhosis and HCC BCLC B with TACE refractoriness. She received 8 mg of lenvatinib for 2 weeks and began to experience worsening hypertension, bilateral pleural effusion, pedal edema, hypoalbuminemia, hypercholesterolemia, and proteinuria. After exclusion of all possible causes, lenvatinib-induced nephrotic syndrome (NS) was diagnosed. One week after discontinuing the drug, her symptoms gradually improved. To date, there have been only a handful of reported cases of lenvatinib-induced nephrotoxicity. We report herein the case of lenvatinib-induced NS in a cirrhotic patient with HCC with resolution of symptoms in a short period after drug discontinuation. In addition, we reviewed all reported cases of lenvatinib-induced nephrotoxicity.

1. Introduction

Lenvatinib is an oral small-molecule multiple tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptor 1–3 (VEGFR1–3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and rearranged during transfection (RET) [1, 2]. It has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC) [3–5]. A recent randomized controlled study showed that it was noninferior to sorafenib in terms of overall survival (OS), but was associated with: longer progression-free survival, longer time to progression, and higher objective response rate in comparison to sorafenib based on results of REFLECT trial [6]. The most common adverse events of lenvatinib are hypertension, diarrhea, decreased weight and appetite, and proteinuria. We reported herein a cirrhotic patient with unresectable HCC who received lenvatinib and developed nephrotic syndrome due to lenvatinib treatment.

2. Case Report

A 67-year-old Thai female was hospitalized due to worsening dyspnea and orthopnea for 1 week. She was previously diagnosed with nonalcoholic steatohepatitis (NASH)-related Child–Pugh A cirrhosis (6 points) and Barcelona Clinic Liver Cancer (BCLC) stage B HCC 6 months previously. Abdominal computed tomography (CT) revealed a cirrhotic liver with many arterial enhancing lesions in both hepatic lobes with rapid wash-out in portal and delayed phases. The largest tumor size of 4.0 × 4.2 × 4.5 cm in segments V/VII indicated multifocal HCC with the absence of portal vein invasion and thrombosis. She received locoregional therapy for HCC by transarterial chemoembolization (TACE) 2
times but failed to experience significant response. CT at 1-month follow-up after TACE demonstrated a viable tumor 3.1 \times 2.9 \text{ cm} at hepatic segment V (Figure 1). After discussion with patient for further treatments, she was switched to systemic therapy using a molecular targeted agent. An 8 mg daily dose of lenvatinib was prescribed 2 weeks before this hospital admission. Her medical history included well-controlled hypertension, dyslipidemia, type 2 diabetes mellitus, and Graves' disease treated with radioactive iodine.

Physical examination revealed body temperature of 36.2°C, blood pressure (BP) of 190/120 mm Hg (baseline BP 110/60), pulse rate of 110/min, respiratory rate of 24/min, puffy eye lids, decreased breath sounds and dullness on percussion at lower half of the right lung, and bilateral pedal edema. Chest X-ray (CXR) showed moderate right pleural effusion (Figure 2(a)). Pleural fluid analysis exhibited white blood cell (WBC) of 111 cells/µL (neutrophil 28%; lymphocyte 72%), protein of 1.5 g/dL, lactate dehydrogenase of 78 U/L, and no organism on Gram stain and culture indicating transudative profile. Serum biochemical tests showed total bilirubin of 1.2 mg/dL, direct bilirubin of 0.6 mg/dL, SGOT of 50 U/L, SGPT of 34 U/L, alkaline phosphatase of 99 U/L, BUN of 29 mg/dL, creatinine of 0.9 mg/dL, eGFR of 66 mL/min/1.73 m², albumin of 2.0 g/dL, protein of 6.7 g/dL, LDH of 238 U/L, and cholesterol of 260 mg/dL. Urinalysis showed red blood cell and WBC of 0-1 cell/high power field (HPF) and 3⁺ albumin. The 24-hour urine albumin was 7.01 g/day. The thyroid function test was normal. The diagnosis of nephrotic syndrome (NS) was definitive. After exclusion of other possible causes of NS including HIV, HBV, HCV, and autoimmune diseases, the diagnosis of lenvatinib-induced NS with worsening hypertension was made. Lenvatinib was immediately discontinued due to this serious adverse event.

One week after discontinuation of lenvatinib and supportive therapy, the patient symptoms gradually improved with a reduction of right pleural effusion (Figure 2(b)) and lowering of the urine protein creatinine ratio (UPCR) from 9.7 to 5.6 g/day after 2 weeks. After discussion with the patient and her family, the decision was made to give supportive care for her HCC for a while. Six months after stopping lenvatinib, UPCR declined to subnephrotic range proteinuria of 0.95 g/day as well as 24-hour urine albumin was only 0.54 g/day. Due to the patient having good performance status as well as preserved liver function, the second line systemic therapy was prescribed with 180 mg of nivolumab. The patient had well-tolerated to treatment with 7 months courses of stable disease by follow-up imaging. Besides, proteinuria was closed follow-up every outpatient visit and demonstrated no evidence of recurrence.
I here have been very few reported cases of lenvatinib-induced nephrotoxicity published in medical journals. We reported herein a case of lenvatinib-induced NS in a cirrhotic patient with HCC, which developed within 2 weeks after beginning a course of 8 mg lenvatinib. Resolution of symptoms began soon after discontinuation of medication. Among molecular targeted agents, lenvatinib is a TKI that inhibits many growth factors and is prescribed for the treatment of many types of cancers including thyroid cancer and HCC. The most common adverse events associated with lenvatinib include hypertension (42%), diarrhea (39%), decreased appetite (34%), decreased weight (31%), and proteinuria (25%) [6].

Preclinical studies in human HCC models have reported that lenvatinib has potent antiangiogenic activity, mainly through the pathways of VEGFR and FGFR inhibition [7]. The VEGF pathway regulates angiogenesis which is an essential event in tumor growth and metastasis which provides oxygen and nutrients to tumor cells. Targeting the VEGFR-mediated pathway can lead to starvation, hypoxia, and tumor cell death [2].

Proteinuria associated with angiogenesis inhibition is the most common renal side effect of anti-VEGF drugs with a prevalence ranging from 21 to 63% and frequently occurring with hypertension. Due to VEGFR binding in glomerular and peritubular endothelium, as well as in mesangial cells in normal conditions, this binding process plays a role in the maintenance of the glomerular basement membrane structure and proper glomerular function. The drugs block VEGFR and may induce renal abnormalities, especially in renovascular function that includes hypertension and proteinuria. Moreover, there have been reported patients developing renal thrombotic microangiopathy (TMA) cause by VEGF trap and multitargeted TKI [9]. The presentative symptoms can be mimicked with nephrotic syndrome. Potential mechanisms of lenvatinib-induced proteinuria include postexercise proteinuria-like

| Adverse events | CTCAE grade | CTCAE description | Management |
|----------------|-------------|-------------------|------------|
| Proteinuria    | 1           | 0.15–1.0 g/24 h   | None       |
|                | 2           | >1.0–3.5 g/24 h   | (i) Hold lenvatinib until proteinuria resolves to ≤2.0 g/24 h (ii) Consider consult nephrology |
|                | 3           | >3.5 g/24h        | (i) Hold lenvatinib until proteinuria resolves to ≤2.0 g/24 h (ii) Referral to nephrology |
|                | 4           | Nephrotic syndrome| (i) Discontinue lenvatinib permanently (ii) Referral to nephrology |

Table 1: Common adverse events and recommended management for lenvatinib treatment.

CTCAE, Common Terminology Criteria for Adverse Events; g, gram; h, hours.

3. Discussion

There have been very few reported cases of lenvatinib-induced nephrotoxicity published in medical journals. We reported herein a case of lenvatinib-induced NS in a cirrhotic patient with HCC, which developed within 2 weeks after beginning a course of 8 mg lenvatinib. Resolution of symptoms began soon after discontinuation of medication. Among molecular targeted agents, lenvatinib is a TKI that inhibits many growth factors and is prescribed for the treatment of many types of cancers including thyroid cancer and HCC. The most common adverse events associated with lenvatinib include hypertension (42%), diarrhea (39%), decreased appetite (34%), decreased weight (31%), and proteinuria (25%) [6].

Preclinical studies in human HCC models have reported that lenvatinib has potent antiangiogenic activity, mainly through the pathways of VEGFR and FGFR inhibition [7]. The VEGF pathway regulates angiogenesis which is an essential event in tumor growth and metastasis which provides oxygen and nutrients to tumor cells. Targeting the VEGFR-mediated pathway can lead to starvation, hypoxia, and tumor cell death [2].

Proteinuria associated with angiogenesis inhibition is the most common renal side effect of anti-VEGF drugs with a prevalence ranging from 21 to 63% and frequently occurring with hypertension. Due to VEGFR binding in glomerular and peritubular endothelium, as well as in mesangial cells in normal conditions, this binding process plays a role in the maintenance of the glomerular basement membrane structure and proper glomerular function. The drugs block VEGFR and may induce renal abnormalities, especially in renovascular function that includes hypertension and proteinuria. Moreover, there have been reported patients developing renal thrombotic microangiopathy (TMA) cause by VEGF trap and multitargeted TKI [9]. The presentative symptoms can be mimicked with nephrotic syndrome. Potential mechanisms of lenvatinib-induced proteinuria include postexercise proteinuria-like
Table 2: A summary of all 8 patients with lenvatinib-induced renal toxicity published in English literature from 2019 to 2020.

| Patient | Gender/age (year) | Race | Cancer | Lenvatinib dose (per day)/duration (month) | Clinical presentations | Renal function: creatinine (mg/dL)/eGFR (mL/min/1.73m²) | Urinalysis/24-hour protein urine (g) | Renal histological finding | Treatment | Outcome |
|---------|-------------------|------|--------|--------------------------------------------|------------------------|-------------------------------------------------|---------------------------------|--------------------------------|-----------|---------|
| 1, 2018 [23] | F/36 | Caucasian | Medullary thyroid carcinoma | 24 mg/19 | Worsening HT, ankle edema | Normal | NA/3.1 g | FSGS | Discontinued lenvatinib | No proteinuria in 1 year |
| 2, 2018 [23] | F/70 | Japan | Papillary thyroid carcinoma | 24 mg/26 | Worsening HT, legs edema | 1.12/37.4 | WBC <1, RBC 5–9 cells/HPF/3.5 g | TMA | Decreased dose to 8 mg of lenvatinib and discontinuation | Partial recovery in 2 months |
| 3, 2018 [16] | F/79 | Japan | Papillary thyroid carcinoma | 10 mg/3 | Worsening HT, generalized edema | 1.17/34 | RBC 20–29 cells/HPF/11.8 g | FSGS | Discontinued lenvatinib | Complete recovery in 15 months |
| 4, 2018 [22] | M/44 | Caucasian | Papillary thyroid carcinoma | 24 mg/6 | Worsening HT | 1.90/NA | NA/3.5 g | FSGS, tubulointerstitial vascular necrosis, TMA-like pattern | Decreased dose to 10 mg of lenvatinib and discontinued | Partial recovery in 1 month |
| 5, 2018 [22] | F/59 | Caucasian | Adenoid cystic carcinoma of the minor salivary gland | 24 mg/15 | Acute renal failure (tubulointerstitial nephropathy by clinics) | 2.81/NA | No sediment/<1 g | Not performed | Discontinued lenvatinib, Prednisolone 40 mg taper in 6 months | Renal function improved in 10 days |
| 6, 2018 [24] | M/67 | Caucasian | Papillary thyroid carcinoma | 24 mg/9 | Worsening HT and renal function | 2.46/26.0 | NA/NA | Not performed | Discontinued lenvatinib | Partial recovery in 8 months |
| 7, 2020 [25] | M/56 | Taiwan | Papillary thyroid carcinoma | 20 mg/1 | Worsening HT, legs edema | 0.56/115 | Trace hematuria/9.9 g | Not performed | Decreased dose to 10 mg of lenvatinib and discontinued with sorafenib replacement | Partial recovery in 5 months |
| 8 (our case), 2020 | F/67 | Thai | Hepatocellular carcinoma | 8/0.5 | Worsening HT, bilateral pleural effusion, legs edema | 0.9/66 | WBC 0–1, RBC 0–1 cells/HPF/7.01 g | Not performed | Discontinued lenvatinib | Partial recovery in 1 week |

FSGS, focal segmental glomerulosclerosis; TMA, thrombotic microangiopathy; HT, hypertension; AEs, adverse events; WBC, white blood cells; RBC, red blood cells; F, female; M, male; NA, not applicable.
syndrome, perturbation of podocyte-endothelial VEGF axis signaling, podocyte protein junction downregulation, subacute glomerular thrombotic microangiopathy, and additional pathogenic factors such as hypertensive injury [10]. The exact mechanism and factors associated with the occurrence and severity of proteinuria are unknown [11, 12]. According to the reported studies in patients with thyroid cancer, lenvatinib-induced proteinuria can be observed at any time after drug initiation. The mean duration of the development of renal adverse effects after lenvatinib initiation was 43 (range 5–799) days [13–16]. Management should be dose reduced to minimize the risk of renal adverse events or complete drug discontinuation. Data showed that patients can recover within 9 weeks after stopping lenvatinib [14].

The maximum recommended dose of lenvatinib for HCC treatment is 12 mg per day, whereas 24 mg per day can be prescribed for radioiodine-refractory thyroid cancer [13]. The half-dose reduction of lenvatinib for HCC treatment may be due to the fact that lenvatinib is metabolized in the liver [17].

Management of adverse events includes supportive care, dose modification, and discontinuation of lenvatinib in cases with grade 4 adverse events. Clinical practice management of adverse events from lenvatinib-induced proteinuria according to the Common Terminology Criteria for Adverse Events (CTCAE) are listed in Table 1 [12, 17–20]. Regarding proteinuria, lenvatinib can induce renal failure defined as a decline of eGFR in the long-term analysis. They might be associated with glomerular damage, with secondary proteinuria and tubular injury, especially with long-term lenvatinib used duration over 2 years [21, 22].

Our patient rapidly developed NS just 2 weeks after lenvatinib treatment which was faster than other reported cases. Multiple patient comorbidities, including long-standing hypertension, diabetes, dyslipidemia, old age, and decompensated cirrhosis, likely predisposed the patient for the rapid development of NS. The limitation of our reported patient was an absence of definite diagnosis by renal biopsy. However, despite the lack of histopathologic findings from renal parenchyma, the diagnosis of lenvatinib-induced NS was suspected due to the improvement of patient symptoms and reduction of proteinuria following discontinuation of lenvatinib within 1 week [19].

In addition, we retrospectively reported a literature review. A total of eight patients with lenvatinib-induced renal adverse effects have currently been reported in the literature (Table 2) [16, 22–25]. Cases consisted of 3 males and 5 females with the mean age of 59.8 ± 13.3 (range: 36–79) years. There were 4 Asians and 4 Caucasians. Of the eight patients, thyroid carcinoma was the most common cancer (n = 6, 75.0%), followed by HCC and carcinoma of the minor salivary gland (n = 1, 12.5%). The dosage of lenvatinib ranged from 8 to 24 mg, and the duration of treatment ranged from 0.5 to 48 months. Compared to prior reported cases, our patient received the lenvatinib with the lowest dose (8 mg) and shortest duration (2 weeks). Regarding the clinical manifestations of nephrotoxicity, worsening hypertension was the most common event (n = 7, 87.5%), followed by edema (n = 5, 62.5%), renal function decline (n = 2, 25.0%), and pleural effusion (n = 1, 12.5% in our case). The 24-hour urine protein ranged from <1 to 11.8 g/day. With respect to renal pathology, focal segmental glomerulosclerosis and thrombotic microangiopathy were noted in 3 and 1 patients, respectively, while 4 patients did not complete a renal biopsy. The management in all patients (n = 8, 100%) was lenvatinib discontinuation. Three patients had been failed for prior dose reduction; one patient was treated with 40 mg of prednisolone which was tapered off within 6 months, and another one was treated by sorafenib replacement. The treatment outcomes for lenvatinib-induced renal toxicity were excellent: complete resolution (n = 2, 25.0%) and partial resolution (n = 6, 75.0%). The recovery duration after the discontinued use of lenvatinib ranged from 1 week to 15 months. Our case study patient reported the shortest symptoms recovery time of 1 week.

4. Conclusion

To date, there have been only a handful of reported cases of lenvatinib-induced nephrotoxicity. We report herein the case of lenvatinib-induced NS in a cirrhotic patient with HCC with resolution of symptoms in a short period after drug discontinuation.

Abbreviations

BCLC: Barcelona Clinic Liver Cancer
BP: Blood pressure
CT: Computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
CXR: Chest X-ray
eGFR: Estimated glomerular filtration rate
FGFR: Fibroblast growth factor receptor
HBV: Hepatitis B virus
HCC: Hepatocellular carcinoma
HCV: Hepatitis C virus
HIV: Human immunodeficiency virus
HPF: High power field
KIT: Stem cell factor receptor
LDH: Lactate dehydrogenase
NASH: Nonalcoholic steatohepatitis
NS: Nephrotic syndrome
OS: Overall survival
PDGFR: Platelet-derived growth factor receptor
RET: Rearranged during transfection
SGOT: Serum glutamic-oxaloacetic transaminase
SGPT: Serum glutamic pyruvic transaminase
TACE: Transarterial chemoembolization
TKI: Tyrosine kinase inhibitor
TMA: Thrombotic microangiopathy
UPCR: Urine protein creatinine ratio
VEGFR: Vascular endothelial growth factor receptor
WBC: White blood cell.
Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] Z. T. Al-Salama, Y. Y. Syed, and L. J. Scott, "Lenvatinib: a review in hepatocellular carcinoma," Drugs, vol. 79, no. 6, pp. 665–674, 2019.
[2] Y. Zhao, Y. N. Zhang, K. T. Wang, and L. Chen, "Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy," Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, vol. 1874, no. 1, Article ID 188391, 2020.
[3] European Association for the Study of the Liver, "Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma," Journal of Hepatology, vol. 69, no. 1, pp. 182–236, 2018.
[4] J. A. Marrero, L. M. Kulik, C. B. Sirlin et al., "Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases," Hepatology, vol. 68, no. 2, pp. 723–750, 2018.
[5] M. Omata, A. L. Cheng, N. Kokudo et al., "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update," Hepatol Int, vol. 11, no. 4, pp. 317–370, 2017.
[6] M. Kudo, R. S. Finn, S. Qin et al., "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial," The Lancet, vol. 391, no. 10126, pp. 1163–1173, 2018.
[7] M. Matsuki, T. Hoshi, Y. Yamamoto et al., "Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models," Cancer Medicine, vol. 7, no. 6, pp. 2641–2653, 2018.
[8] Y. Hyogo, N. Kiyota, N. Otsuki et al., "Thrombotic microangiopathy with severe proteinuria induced by lenvatinib for radioactive iodine-refractory papillary thyroid carcinoma," Case Reports in Oncology, vol. 11, no. 3, pp. 735–741, 2018.
[9] M. Delsante, J. M. Monroy-Trujillo, N. Carter-Monroe, D. W. Ball, and A. Z. Rosenberg, "Lenvatinib-related renal microangiopathy: a case series," Virchows Archiv, vol. 480, pp. 467–473, 2021.
[10] H. Izzedine, C. Massard, J. P. Spano, F. Goldwasser, D. Khayat, and J. C. Soria, "VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management," European Journal of Cancer, vol. 46, no. 2, pp. 439–448, 2010.
[11] V. Launay-Vacher and G. Deray, "Hypertension and proteinuria: a class-effect of antiangiogenic therapies," Anti-Cancer Drugs, vol. 20, no. 1, pp. 81–82, 2009.
[12] M. L. C. Santos, B. B. de Brito, F. A. F. da Silva, A. C. D. S. Botelho, and F. F. de Melo, "Nephrotoxicity in cancer treatment: an overview," World Journal of Clinical Oncology, vol. 11, no. 4, pp. 190–204, 2020.
[13] M. Schlumberger, M. Tahara, L. J. Wirth et al., "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer," New England Journal of Medicine, vol. 372, no. 7, pp. 621–630, 2015.
[14] R. I. Haddad, M. Schlumberger, L. J. Wirth et al., "Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes," Endocrine, vol. 56, no. 1, pp. 121–128, 2017.
[15] O. V. Ancker, M. Wehland, J. Bauer, M. Infanger, and D. Grimm, "The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors," International Journal of Molecular Sciences, vol. 18, no. 3, 2017.
[16] Y. Furuto, H. Hashimoto, A. Namikawa et al., “Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report,” BMC Nephrology, vol. 19, no. 1, p. 273, 2018.
[17] L. Rimassa, R. Danesi, T. Pressiani, and P. Merle, “Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma,” Cancer Treatment Reviews, vol. 77, pp. 20–28, 2019.
[18] E. Inc, Lentima (Lenvatinib) Prescribing Information, Eisai Inc, Bunkyo, Japan, 2020.
[19] M. E. Cabanillas and S. Takahashi, “Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer,” Seminars in Oncology, vol. 46, no. 1, pp. 57–64, 2019.
[20] N. Dctd, "Cancer therapy evaluation program, common Terminology Criteria for adverse events," 2003, https://ctepcancer.gov.
[21] C. Masaki, K. Sugino, S. Kobayashi et al., "Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients," BMC Cancer, vol. 21, no. 1, p. 894, 2021.
[22] S. Cavalieri, L. Cosmai, A. Genderini et al., "Lenvatinib-induced renal failure: two first-time case reports and review of literature," Expert Opinion on Drug Metabolism and Toxicology, vol. 14, no. 4, pp. 379–385, 2018.
[23] K. Fleming, J. McGuinness, D. Kippen, H. Glen, and P. Spiliopoulou, "A case of lenvatinib-induced focal segmental glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer," Case Reports in Oncological Medicine, vol. 2018, Article ID 6927639, 6 pages, 2018.
[24] L. Paschke, T. Lincke, K. S. Muhlgberg, W. J. Jabs, T. H. Lindner, and R. Paschke, "Anti VEGF-TKI treatment and new renal adverse events not reported in phase III trials," European Thyroid Journal, vol. 7, no. 6, pp. 308–312, 2018.
[25] H. Che, K. T. C. Yang, Y. S. Lin, C. Y. Hsu, Y. C. Ou, and M. C. Tung, "Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: a case report," World Journal of Clinical Cases, vol. 8, no. 20, pp. 4883–4894, 2020.